Skip to main content

Market Overview

Alkermes: Q2 Earnings Insights



Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share rose 400.00% over the past year to $0.30, which beat the estimate of $0.12.

Revenue of $303,717,000 rose by 22.70% year over year, which beat the estimate of $278,700,000.


Alkermes raised FY21 adjusted EPS guidance from $0.37-$0.62 to $0.52-$0.70.

The company also boosted sales forecast from $1.1 billion-$1.17 billion to $1.145 billion-$1.185 billion.

Conference Call Details

Date: Jul 28, 2021

Time: 08:00 AM

ET Webcast URL:

Recent Stock Performance

52-week high: $25.74

Company's 52-week low was at $15.35

Price action over last quarter: Up 10.84%

Company Description

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.


Related Articles (ALKS)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at